Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark G Lebwohl

Showing results (21-30 of 209) with videos related to

Pageof 21
Sort By:
Dermatologic Therapy|September 24, 2004
Biologics in combination with nonbiologics: efficacy and safetyWilliam G Stebbins, Mark G Lebwohl
JAMA Dermatology|January 22, 2025
Comments on Consensus for Generalized Pustular PsoriasisShayan Waseh, Sylvia Hsu, Mark G Lebwohl
Lancet (London, England)|August 31, 2024
Spesolimab use in generalised pustular psoriasis flares - Authors' replyMark G Lebwohl, Christian Thoma, Thomas Haeufel
The Journal of Investigative Dermatology|May 15, 2015
IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A TherapiesAndrew Blauvelt, Mark G Lebwohl, Robert Bissonnette
The British Journal of Dermatology|November 27, 2023
Safety and efficacy of dual tyrosine kinase 2 inhibitor and monoclonal antibody therapy for psoriasis and psoriatic arthritisSophie Guénin, Elizabeth Andrews, Mark G Lebwohl
Cutis|January 11, 2011
The role of human papillomavirus in common skin conditions: current viewpoints and therapeutic optionsMark G Lebwohl, Ted Rosen, Eggert Stockfleth
Cutis|March 20, 2018
Melkersson-Rosenthal syndrome successfully treated with adalimumabEllen H de Moll, Mark G Lebwohl
Cutis|September 11, 2020
Apremilast and systemic retinoid combination treatment for moderate to severe palmoplantar psoriasisTali Czarnowicki, B Peter Rosendorff, Mark G Lebwohl
Journal of Psoriasis and Psoriatic Arthritis|September 19, 2024
Retrospective Analysis in Patients With Moderate to Severe Plaque Psoriasis Treated With Tildrakizumab: Real-Life Clinical DataNancy W Wei, Sunny Chi, Mark G Lebwohl
JAAD Case Reports|March 20, 2023
Spesolimab use in treatment of pyoderma gangrenosumSophie H Guénin, Saakshi Khattri, Mark G Lebwohl
Pageof 21

Showing results (21-30 of 209) with videos related to

Sort By:
Pageof 21
Dermatologic Therapy|September 24, 2004
Biologics in combination with nonbiologics: efficacy and safetyWilliam G Stebbins, Mark G Lebwohl
JAMA Dermatology|January 22, 2025
Comments on Consensus for Generalized Pustular PsoriasisShayan Waseh, Sylvia Hsu, Mark G Lebwohl
Lancet (London, England)|August 31, 2024
Spesolimab use in generalised pustular psoriasis flares - Authors' replyMark G Lebwohl, Christian Thoma, Thomas Haeufel
The Journal of Investigative Dermatology|May 15, 2015
IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A TherapiesAndrew Blauvelt, Mark G Lebwohl, Robert Bissonnette
The British Journal of Dermatology|November 27, 2023
Safety and efficacy of dual tyrosine kinase 2 inhibitor and monoclonal antibody therapy for psoriasis and psoriatic arthritisSophie Guénin, Elizabeth Andrews, Mark G Lebwohl
Cutis|January 11, 2011
The role of human papillomavirus in common skin conditions: current viewpoints and therapeutic optionsMark G Lebwohl, Ted Rosen, Eggert Stockfleth
Cutis|March 20, 2018
Melkersson-Rosenthal syndrome successfully treated with adalimumabEllen H de Moll, Mark G Lebwohl
Cutis|September 11, 2020
Apremilast and systemic retinoid combination treatment for moderate to severe palmoplantar psoriasisTali Czarnowicki, B Peter Rosendorff, Mark G Lebwohl
Journal of Psoriasis and Psoriatic Arthritis|September 19, 2024
Retrospective Analysis in Patients With Moderate to Severe Plaque Psoriasis Treated With Tildrakizumab: Real-Life Clinical DataNancy W Wei, Sunny Chi, Mark G Lebwohl
JAAD Case Reports|March 20, 2023
Spesolimab use in treatment of pyoderma gangrenosumSophie H Guénin, Saakshi Khattri, Mark G Lebwohl
Pageof 21